BOD - Trademark Details
Status: 602 - Abandoned-Failure To Respond Or Late Response
Image for trademark with serial number 88835504
Serial Number
88835504
Word Mark
BOD
Status
602 - Abandoned-Failure To Respond Or Late Response
Status Date
2021-09-17
Filing Date
2020-03-16
Mark Drawing
5000 - Illustration: Drawing with word(s)/letter(s)/number(s) in Stylized form Typeset
Attorney Name
Law Office Assigned Location Code
M80
Employee Name
FOSTER, ALEXANDRA M.
Statements
Indication of Colors claimed
Color is not claimed as a feature of the mark.
Description of Mark
The mark consists of the word BOD in a stylized font.
Goods and Services
Nutritional supplements; dietary supplements; vitamin supplements; natural healthcare preparations for general health and well-being and for the treatment of metabolic diseases and disorders, namely, diabetes, type II diabetes, nephropathy, inflammation of the intestine, neuroinflammatory disorders, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism, obesity associated with diabetes, and for the treatment of pain, neuropathic pain, neurogenic pain, cancer pain, peri-operative pain, oncology, cancer symptoms, multiple sclerosis, spasticity, MS spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), Dup15q syndrome, and Doose syndrome, bladder disfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, Lennox-Gastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory connective tissue diseases, arthritis, neurodegenerative diseases, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, cerebral palsy, brain, movement, ocular motility, peripheral neuropathy, neurogenic symptoms, hypoxicischemic encephalopathy, neonatal hypoxic encephalopathy, stroke, motion sickness, AIDS (HIV) and AIDS wasting, asthma, breathing disorders, hepatitis C, migraines, multiple sclerosis, analgesia, Tourette syndrome, bulimia, psychiatric disorders, namely, bipolar disorder, dementia, anxiety disorders, Alzheimer's disease, schizophrenia, and drug, alcohol and nicotine abuse, autism, nausea, vomiting, loss of appetite, muscle tension, muscle spasms, epilepsy, glaucoma, arthritis, Parkinson's disease, gastrointestinal illness, anxiety, bi-polar disorder, depression, insomnia, and for topical treatment of skin inflammation, namely, eczema, psoriasis, atopic dermatitis, acne, rosacea, lichen planus, bullous pemphigold, vasculitis, granuloma annulare and erythroderma; natural pharmaceutical preparations for general health and well-being and for the treatment of metabolic diseases and disorders, namely, diabetes, type II diabetes, nephropathy, inflammation of the intestine, neuroinflammatory disorders, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism, obesity associated with diabetes, and for the treatment of pain, neuropathic pain, neurogenic pain, cancer pain, peri-operative pain, oncology, cancer symptoms, multiple sclerosis, spasticity, MS spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), Dup15q syndrome, and Doose syndrome, bladder disfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, Lennox-Gastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory connective tissue diseases, arthritis, neurodegenerative diseases, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, cerebral palsy, brain, movement, ocular motility, peripheral neuropathy, neurogenic symptoms, hypoxicischemic encephalopathy, neonatal hypoxic encephalopathy, stroke, motion sickness, AIDS (HIV) and AIDS wasting, asthma, breathing disorders, hepatitis C, migraines, multiple sclerosis, analgesia, Tourette syndrome, bulimia, psychiatric disorders, namely, bipolar disorder, dementia, anxiety disorders, Alzheimer's disease, schizophrenia, and drug, alcohol and nicotine abuse, autism, nausea, vomiting, loss of appetite, muscle tension, muscle spasms, epilepsy, glaucoma, arthritis, Parkinson's disease, gastrointestinal illness, anxiety, bi-polar disorder, depression, insomnia, and for topical treatment of skin inflammation, namely, eczema, psoriasis, atopic dermatitis, acne, rosacea, lichen planus, bullous pemphigold, vasculitis, granuloma annulare and erythroderma; any the foregoing containing hemp extracts are derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2020-03-20
Primary Code
005
Correspondences
Name
Thomas L. Holt
Address
Please log in with your Justia account to see this address.
Trademark Events
Event DateEvent Description
2020-03-19NEW APPLICATION ENTERED IN TRAM
2020-03-20NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2020-06-08ASSIGNED TO EXAMINER
2020-06-09ASSIGNED TO EXAMINER
2020-08-06TEAS VOLUNTARY AMENDMENT RECEIVED
2020-08-06PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
2020-08-31ASSIGNED TO EXAMINER
2020-09-05NON-FINAL ACTION WRITTEN
2020-09-05NON-FINAL ACTION E-MAILED
2020-09-05NOTIFICATION OF NON-FINAL ACTION E-MAILED
2021-03-03TEAS RESPONSE TO OFFICE ACTION RECEIVED
2021-03-03CORRESPONDENCE RECEIVED IN LAW OFFICE
2021-03-04TEAS/EMAIL CORRESPONDENCE ENTERED
2021-03-06FINAL REFUSAL WRITTEN
2021-03-06FINAL REFUSAL E-MAILED
2021-03-06NOTIFICATION OF FINAL REFUSAL EMAILED
2021-09-17ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
2021-09-17ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND